Peptide-mediated regulation of the allergic immune response

Immunology and Cell Biology

Volumn 74, Issue 2, 1996, Pages 180-186

  Hoyne, Gerard F ^a   Lamb, Jonathan R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Allergy; Cytokines; Desensitization; Immunotherapy; Peptides; T cells; Tolerance

Indexed keywords

ALLERGEN;

ALLERGY; ARTICLE; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INTRANASAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; T LYMPHOCYTE SUBPOPULATION;

EID: 0029899198     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1038/icb.1996.25     Document Type: Article

References (88)

1. Finkelman FD, Holmes J, Katona IM et al. Lymphokine control of in vivo immunoglobulin isotype selection. Ann. Rev. Immunol. 1990; 8: 303-33.
2. Street NE, Mosmann TR. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J. 1991; 5: 171-7.
3. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J. Immunol 1988; 140: 4245-52.
4. Fiorentino DF, Zlotnik A, Vieira P et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 1991; 146: 3444-51.
5. de Waal Malefyt R, Haanen J, Spits H et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific Human T cell proliferation by diminishing the antigen-present ing capacity of monocytes via downregulation of class II Major Histocompatibility Complex expression. J. Exp. Med. 1991; 174: 915-24.
6. + T lymphocytes in atopic patients. J. Immunol. 1990; 144: 4651-6.
7. Wierenga EA, Snoek M, Jansen HM, Bos JD, Kapsenburg ML. Comparison of diversity and function of house dust mite-specific T lymphocyte clones from atopic and non-atopic donors. Eur. J. Immunol. 1990; 20: 1519-26.
8. Kapsenberg ML, Wierenga EA, Bos JD, Jansen HM. Functional subsets of allergen-reactive human CD4+ T cells. Immunol. Today 1991; 12: 392-5.
9. Wierenga EA, Snoek M, Janses HM, Bos JD, van Lier RAW, Kapsenburg ML. Human atopen-specific types 1 and 2 T helper cell clones. J. Immunol. 1991; 147: 2942-9.
10. + T cell clones. J. Immunol. 1992; 148: 738-45.
11. Romagnani S. Lymphokine production by human T cells in disease states. Ann. Rev. Immunol. 1994; 12: 227-58.
12. O'Hehir RE, Garman RD, Greenstein JL, Lamb JR. The specificity and regulation of T-cell responsiveness to allergens. Ann. Rev. Immunol. 1991; 9: 67-95.
13. Durham SR, Ying S, Varney VA et al. Cytokine messenger RNA expression for IL-3, IL-4, IL-5, and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. J. Immunol. 1992; 148: 2390-4.
14. Robinson DS, Hamid Q, Ying S et al. Predominant Th2 -like bronchoalvcolar T-lymphocyte population in atopic asthma. N. Engl. J. Med. 1992; 326: 298-304.
15. Del Prete GF, De Carli M, D'Elios MM et al. Allergen exposure induces the activation of allergen-specific Th2 cells in the airway mucosa of patients with allergic respiratory disorders. Eur. J. Immunol. 1993; 23: 1445.
16. Ishizaka K, Ishizaka T. Allergy. In: Paul WE (ed.) Fundamental Immunology. New York: Raven Press, 1989; 867-88.
17. Wierenga EA, Backx B, Snoek M, Koenderman L, Kapsenburg ML. Relative contribution of human types 1 and 2 T-helper cell derived eosinophilotrophic cytokines to development of eosinophilia. Blood 1993; 82: 1471.
18. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin-4 production in CD4+ T cells from allergic patients. J. Exp. Med. 1993; 178: 2123.
19. Jutel MP, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR. Bee venom immunotherapy results in a decrease in IL-4 and IL-5 and an increase of IFN-γ secretion in specific allergen stimulated cultures. J. Immunol. 1995; 154: 4187-94.
20. Varney VA, Hamid QA, Gaga M et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late phase cutaneous responses. J. Clin. Invest. 1993; 92: 644-51.
21. Sedgwick JD, Holt PG. Induction of IgE-isotype specific tolerance by passive antigenic stimulation of the respiratory mucosa. Immunology 1983; 50: 625-30.
22. Sedgwick JD, Holt PG. Suppression of IgE response in inbred rats by repeated respiratory tract exposure to antigen: responder phenotype influences iso type specificity of induced tolerance. Eur. J. Immunol. 1984; 14: 893-7.
23. Sedgwick JD, Holt PG. Down-regulation of immune responses to inhaled antigen: Studies on the mechanism of induced suppression. Immunology 1985; 56: 635-42.
24. Holt PG, Batty JE, Turner KJ. Inhibition of specific IgE responses in mice by pre-exposure to inhaled antigen. Immunology 1981; 42: 409-17.
25. Holt PG, Leivers S. Tolerance induction via antigen inhalation: isotype specificity, stability and involvement of suppressor T-cells. Int. Arch. Allergy Appl. Immunol. 1982; 67: 155-60.
26. + T cell-mediated but class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production. J. Exp. Med. 1993; 178: 889-99.
27. - lymphocytes (putative γ/δ T cells). Immunology 1991; 74: 234-9.
28. McMenamin C, Pimm C, McKersey M, Holt PG. Regulation of IgE responses to inhaled antigen in mice by antigen-specific γδ T cells. Science 1994; 265: 1869-71.
29. Holt PG. Immunoprophylaxis of atopy: light at the end of the tunnel? Immunol. Today 1994; 15: 484-9.
30. Holt PG. Down-regulation of immune responses in the lower respiratory tract: the role of alveolar macrophages. Clin. Exp. Immunol. 1986; 63: 261.
31. Herschowitz HB. In defense of the lung: paradoxical role of the pulmonary alveolar macrophage. Ann. Allergy 1985; 55: 634.
32. Bilyk N, Holt PG. Cytokine modulation of the immunosuppressive phenotype of pulmonary alveolar macrophage populations. Immunology 1995; 86: 231-7.
33. Bilyk N, Holt PG. Inhibition of the immunosuppressive activity of resident pulmonary alveolar macrophages by granulocyte/macrophage colony stimulating factor. J. Exp. Med. 1993; 177: 1773.
34. Renz H, Bradley K, Saloga J, Loader J, Larsen GL, Gelfand EW. T cells expressing specific Vβ elements regulate immunoglobulin E production and airways responsiveness in vivo. J. Exp. Med. 1993; 177: 1175-80.
35. Renz H, Lack G, Saloga J et al. Inhibition of IgE production and normalization of airways responsiveness by sensitized CD8 T cells in a mouse model of allergen-induced sensitization. J. Immunol. 1994; 152: 351-60.
36. Holt PG, McMenamin C. Defence against allergic sensitization in the healthy lung: the role of inhalation tolerance. Clin. Exp. Allergy 1989; 19: 255-62.
37. Mowat AM. The regulation of immune responses to dietary antigens. Immunol. Today 1987; 8: 93-8.
38. Fairchild PJ, Thorpe CJ, Travers PJ, Wraith DC. Modulation of the immune response with T-cell epitopes: the ultimate goal for specific immunotherapy of autoimmune disease. Immunology 1994; 81: 487-96.
39. Weiner HL, Friedman A Miller A et al. Oral Tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Ann. Rev. Immunol. 1994; 12: 809-37.
40. Webb S, Morris C, Sprent J. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 1990; 63: 1249-56.
41. Zhang L, Martin DR, Fung-Leung WP, Teh HS, Miller RG. Peripheral deletion of mature CD8+ T antigen-specific T cells after in vivo exposure to male antigen. J. Immunol. 1992; 148: 3740-5.
42. Rocha B, von Boehmer H. Peripheral selection of the T cell repertoire. Science 1991; 251: 1225-8.
43. Morahan G, Allison J, Miller JF. Tolerance of class I histocompatibility antigens expressed extrathymically. Nature 1989; 339: 622-4.
44. Lo D, Burkly LC, Widera G et al. Diabetes and tolerance in transgenic mice expressing class II MHC molecules in pancreatic beta cells. Cell 1988; 53: 159-68.
45. Lo D, Burkly LC, Flavell RA, Palmiter RD, Brinster RL. Tolerance in transgenic mice expressing class II major histocompatibility complex on pancreatic acinar cells. J. Exp. Med. 1989; 170: 87-104.
46. Ohashi PS, Oehen S, Buerki K et al. Ablation of 'tolerance' and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991; 65: 305-17.
47. Oldstone MBA, Nerenberg M, Southern P, Price J, Lewicki H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 1991; 65: 319-31.
48. Guerder S, Meyerhoff J, Flavell R. The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. Immunity 1994; 1: 155-66.
49. Scott B, Liblau R, Degermann S et al. A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity 1994; 1: 73-82.
50. Schonrich G, Kalinke U, Momburg F et al. Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell 1991; 65: 293-304.
51. Schonrich G, Momburg F, Malissen M et al. Distinct mechanisms for extrathymic T cell tolerance due to differential expression of self antigen. Int. Immunol. 1991; 4: 581-90.
52. Ferber I, Schonrich G, Schenkel J, Mellor AL, Hammerling G, Arnold B. Levels of peripheral tolerance induced by different doses of antigen. Science 1994; 263: 674-6.
53. Chen Y, Inobe J-I, Marks R, Gonnella P, Kuchroo VK, Weiner HL. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995; 376: 177.
54. Melamed D, Friedman A. Direct evidence for anergy in T lymphocytes tolerised by oral administration of ovalbumin. Eur. J. Immunol. 1993; 23: 935-42.
55. Whiteacre CC, Gienapp IE, Orosz CG, Bitmar DM. Oral tolerance in experimental autoimmune encephalomyelitis III. Evidence for clonal anergy. J. Immunol. 1991; 147: 2155-63.
56. Miller A, Lider O, Weiner HL. Antigen-driven bystander suppression after oral administration of antigens. J. Exp. Med. 1991; 174: 791-8.
57. Chen Y, Kuchroo VK, Inobe J-I, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265: 1237.
58. Higgins P, Weiner HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J. Immunol. 1988; 140: 440-5.
59. Metzler B, Wraith DC. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int. Immunol. 1993; 5: 1159.
60. Critchfield JM, Racke MK, Zuniga-Pflucker JC et al. T cell deletion in high dose therapy of autoimmune encephalomyelitis. Science 1994; 263: 1139-43.
61. Gaur A, Wiers B, Liu A, Rothbard J, Fathman CG. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 1992; 258: 1491-4.
62. Dick AD, Cheng YF, McKinnon A, Liversidge J, Forrester JV. Nasal administration of retinal antigens suppresses the inflammatory response in experimental allergic uveoretinitis. A preliminary report of intranasal induction of tolerance with retinal antigens. Br. J. Ophthalmol. 1993; 77: 171.
63. Staines NA, Harper N, Ward FJ. Modulation of collagen arthritis by nasal administration of a dominant immunogenic peptide of type II collagen. Immunology 1994; 83 (Suppl. 1): 46 (abstract).
64. Hoyne GF, O'Hehir RE, Wraith DC, Thomas WR, Lamb JR. Inhibition of T cell and antibody responses to the major house dust mite allergen in naive and sensitized mice. J. Exp. Med 1993; 178: 1783-8.
65. Hoyne GF, Callow MG, Kuo M-C, Thomas WR. Inhibition of T cell responses by feeding peptides containing major and cryptic epitopes. Studies with the Der p I allergen. Immunology 1994; 83: 190-5.
66. Hoyne GF, Askonas BA, Hetzel C, Thomas WR, Lamb JR. Regulation of house dust mite responses by inhaled peptide: transient activation precedes the development of tolerance in vivo. Int. Immunol. 1996 (in press).
67. Briner TJ, Kuo M-C, Rogers BR et al. Inhibition of allergen-specific murine T cell responses after subcutaneous injection of T cell epitope-containing peptide. Proc. Natl Acad. Sci. USA 1993; 90: 7608.
68. Kyburz D, Aichele P, Speiser DE, Hengartner H, Zinkernagel RM, Pircher H. T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides. Eur. J. Immunol. 1993; 23: 1956.
69. Kearney ER, Pape KA, Loh DY, Jenkins MK. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1994; 1: 327-39.
70. Vidard L, Colarusso LJ, Benaceraff B. Specific T cell tolerance may be preceded by a primary response. Proc. Natl Acad. Sci. USA 1994; 91: 5627.
71. Renno T, Hahne M, MacDonald HR. Proliferation is a prerequisite for bacterial superantigen-induced T cell apoptosis in vivo. J. Exp. Med. 1995; 181: 2283-7.
72. Hoyne GF, Thomas WR. T cell responses to orally administered antigens: Study of the kinetics of lymphokine production after single and multiple feeds. Immunology 1995; 84: 304-9.
73. Norman PS, Ohman JL, Long AA. Early clinical experience with T cell reactive peptides from cat allergen Fel d 1. J. Allergy Clin. Immunol. 1994; 93: 231.
74. Rogers BL, Bond JF, Craig SJ et al. Potential therapeutic recombinant proteins containing recombined T cell epitopes. Mol. Immunol. 1994; 31: 955.
75. Muller U, Fricker M, Caraballido J, Blaser K. Successful immunotherapy with T-cell epitopes of bee venom phospholipase A2 in 2 patients with bee venom allergy. In: Ring J, Berendt H (ed.) New Trends in Allergy IV. Hamburg: 1996 (in press).
76. Carballido J, Carballido-Perrig N, Kagi MK et al. T cell epitope specificity in human allergic and nonallergic subjects to bee venom phospholipase A2. J. Immunol. 1993; 150: 3582-91.
77. Lesourd B, Paupe J and Thiollet M. Hymenoptera venom immunotherapy I. Induction of T cell immunity by honeybee venom immunotherapy: relationships with specific antibody responses. J. Allergy Clin. Immunol. 1992; 83: 563-71.
78. Einarsson R, Dreborg S, Hammarstrom L. Monitoring of mite Dermatophagoidesfarinae allergen-specific IgG and IgG subclass distribution in patients on immunotherapy. Allergy 1992; 47: 76-82.
79. Pastorello EA, Pravettoni V, Incorvaia C. Clinical and immunological effects of immunotherapy with alum-adsorbed grass allergoid in grass pollen induced hay fever. Allergy 1992; 47: 281-90.
80. Hetzel, Hoyne GF, Kristensen NM, Bourne T, Tsitoura D, Lamb JR. Peptide mediated regulation of allergic diseases. In: Urban RG, Chicz RM (ed.) MHC molecules: expression, assembly and function. Georgetown, TX: Landes, RG Company, 1995; 261-79.
81. Evavold BD, Allen PM. Separation of IL-4 production from Th proliferation by an altered TcR ligand. Science 1991; 252: 1308.
82. Sloan-Lancaster J, Evavold BD, Allen PM. Th2 clonal anergy as a consequence of partial activation. J. Exp. Med. 1994; 180: 1195-205.
83. Nicholson LB, Greer JM, Sobel RA, Lees MB, Kuchroo VK. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 1995; 3: 397-405.
84. Kuchroo VK, Greer JM, Kaul D et al. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J. Immunol. 1994; 153: 3326-36.
85. Gammon G and Sercarz E. How some T cells escape tolerance induction. Nature 1989; 342: 183-5.
86. De Wit D, Van Mechelen M, Ryelandt M et al. The injection of deaggregated gamma globulin in adult mice induces antigen-specific unresponsiveness of T helper type 1 but not type 2 lymphocytes. J. Exp. Med. 1992; 175: 9-14.
87. Burstein HJ, Shea CM, Abbas AK. Aqueous antigens induce in vivo tolerance in IL-2 and IFN-γ producing (Th1) cells. J. Immunol. 1992; 148: 3687-91.
88. Burstein HJ, Abbas AK. In vivo role of interleukin 4 in T cell tolerance induced by aqueous protein antigen. J. Exp. Med. 1993; 177: 457-63.